Table 3.

Risk factors for ≥ Grade 3 immune-related adverse events

Variable		All patient (n = 215)
		Univariate analysis		p	Multivariate analysis		p
		OR	95%CI		OR	95%CI
Age (y.o.)	< 70 vs. ≥ 70	0.56	0.31–1.01	0.052	0.609	0.32–1.14	0.123
Tumor burden (mm)	< 85 vs. ≥ 85	2.89	1.57–5.40	< 0.001	2.13	1.13–4.01	0.020
Histology	NSQ vs SQ	1.13	0.62–2.10	0.067	1.5	0.81–2.78	0.202
Smoking status	Never vs. Former/Current	3.91	1.23–16.47	0.012	3.02	0.91–10.0	0.071
Treatment	NI vs. NICT	1.76	0.99–3.17	0.054	1.07	0.57–2.03	0.824
Early high fever	No vs. Yes	4.05	2.08–8.09	< 0.001	2.52	1.25–5.09	0.010

 ≥ G3 irAEs (n = 94)

y.o. years old, OR odds ratio, CI confidence interval, NSQ non-squamous cell carcinoma, SQ squamous cell carcinoma, NI nivolumab and ipilimumab therapy, NICT nivolumab, ipilimumab, and chemotherapy